| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 39 | 2024 | 319 | 10.360 |
Why?
|
| Lung Neoplasms | 21 | 2024 | 2363 | 2.810 |
Why?
|
| Breast Neoplasms | 25 | 2023 | 3155 | 2.570 |
Why?
|
| Neoplasms | 30 | 2024 | 3168 | 2.280 |
Why?
|
| Neoplasm Metastasis | 24 | 2025 | 1060 | 2.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 12 | 2023 | 1130 | 1.990 |
Why?
|
| Radiotherapy | 13 | 2020 | 319 | 1.640 |
Why?
|
| Radiation Oncology | 12 | 2023 | 125 | 1.510 |
Why?
|
| Antibodies, Monoclonal, Humanized | 8 | 2023 | 1000 | 1.490 |
Why?
|
| Chemoradiotherapy | 4 | 2021 | 327 | 1.170 |
Why?
|
| Combined Modality Therapy | 28 | 2024 | 1719 | 1.130 |
Why?
|
| Radiotherapy, Intensity-Modulated | 12 | 2021 | 190 | 1.080 |
Why?
|
| Anus Neoplasms | 4 | 2009 | 37 | 1.030 |
Why?
|
| Brain Neoplasms | 10 | 2023 | 810 | 1.010 |
Why?
|
| Clinical Clerkship | 7 | 2018 | 119 | 0.990 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 18 | 2021 | 214 | 0.950 |
Why?
|
| Humans | 120 | 2025 | 93132 | 0.890 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2024 | 2543 | 0.770 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 1660 | 0.710 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2020 | 223 | 0.710 |
Why?
|
| Antibodies, Monoclonal | 4 | 2024 | 1385 | 0.680 |
Why?
|
| Radiotherapy Dosage | 17 | 2021 | 477 | 0.670 |
Why?
|
| Radiotherapy, Conformal | 6 | 2020 | 87 | 0.660 |
Why?
|
| Disease-Free Survival | 9 | 2022 | 1171 | 0.640 |
Why?
|
| Female | 54 | 2025 | 48542 | 0.630 |
Why?
|
| Carcinoma, Squamous Cell | 8 | 2012 | 1073 | 0.630 |
Why?
|
| Transforming Growth Factor beta | 2 | 2023 | 346 | 0.610 |
Why?
|
| Curriculum | 6 | 2018 | 590 | 0.600 |
Why?
|
| Immunotherapy | 10 | 2024 | 762 | 0.590 |
Why?
|
| Radiobiology | 1 | 2018 | 13 | 0.550 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2018 | 58 | 0.540 |
Why?
|
| Prognosis | 13 | 2022 | 3890 | 0.530 |
Why?
|
| Aged, 80 and over | 21 | 2024 | 7039 | 0.520 |
Why?
|
| Genetic Therapy | 4 | 2007 | 365 | 0.510 |
Why?
|
| Mastectomy | 3 | 2017 | 262 | 0.490 |
Why?
|
| T-Lymphocytes | 3 | 2021 | 1276 | 0.480 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 916 | 0.480 |
Why?
|
| Glioblastoma | 5 | 2020 | 280 | 0.480 |
Why?
|
| Apoptosis | 8 | 2021 | 1719 | 0.480 |
Why?
|
| Middle Aged | 34 | 2024 | 27535 | 0.470 |
Why?
|
| Phenanthridines | 5 | 2000 | 24 | 0.470 |
Why?
|
| Aged | 33 | 2024 | 20395 | 0.470 |
Why?
|
| Antineoplastic Agents | 8 | 2021 | 2301 | 0.460 |
Why?
|
| Viruses | 3 | 2007 | 64 | 0.450 |
Why?
|
| Career Choice | 2 | 2014 | 153 | 0.450 |
Why?
|
| Ceramides | 4 | 2000 | 35 | 0.440 |
Why?
|
| Cranial Irradiation | 1 | 2014 | 42 | 0.430 |
Why?
|
| Protein Kinase C | 5 | 2000 | 260 | 0.420 |
Why?
|
| Radiation Injuries | 6 | 2020 | 156 | 0.400 |
Why?
|
| Treatment Outcome | 17 | 2023 | 9070 | 0.390 |
Why?
|
| Adult | 32 | 2024 | 27849 | 0.380 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2014 | 121 | 0.370 |
Why?
|
| Survival Rate | 8 | 2024 | 1945 | 0.350 |
Why?
|
| Radiodermatitis | 1 | 2011 | 10 | 0.350 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2012 | 100 | 0.350 |
Why?
|
| Interferon Type I | 2 | 2024 | 163 | 0.350 |
Why?
|
| Prostatic Neoplasms | 4 | 2021 | 1769 | 0.350 |
Why?
|
| Male | 34 | 2025 | 44355 | 0.350 |
Why?
|
| Head and Neck Neoplasms | 6 | 2009 | 1071 | 0.340 |
Why?
|
| Radiation-Sensitizing Agents | 4 | 2001 | 97 | 0.340 |
Why?
|
| Prospective Studies | 9 | 2024 | 4546 | 0.320 |
Why?
|
| Students, Medical | 5 | 2016 | 433 | 0.320 |
Why?
|
| B7-H1 Antigen | 3 | 2024 | 305 | 0.320 |
Why?
|
| Breast | 1 | 2011 | 302 | 0.300 |
Why?
|
| Statistics as Topic | 1 | 2010 | 228 | 0.300 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2018 | 3450 | 0.300 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2019 | 165 | 0.300 |
Why?
|
| MicroRNAs | 4 | 2016 | 581 | 0.300 |
Why?
|
| Gastrointestinal Tract | 2 | 2021 | 196 | 0.300 |
Why?
|
| Program Evaluation | 6 | 2018 | 312 | 0.290 |
Why?
|
| Pneumonia | 2 | 2022 | 192 | 0.280 |
Why?
|
| Obesity | 2 | 2014 | 1014 | 0.280 |
Why?
|
| Liver Neoplasms | 3 | 2024 | 773 | 0.280 |
Why?
|
| Comorbidity | 2 | 2020 | 1003 | 0.280 |
Why?
|
| Ipilimumab | 2 | 2021 | 64 | 0.280 |
Why?
|
| Fluorouracil | 7 | 2009 | 524 | 0.270 |
Why?
|
| Mitomycin | 4 | 2009 | 29 | 0.270 |
Why?
|
| RNA-Binding Proteins | 3 | 2024 | 306 | 0.260 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2008 | 165 | 0.260 |
Why?
|
| Cell Survival | 4 | 2019 | 1002 | 0.260 |
Why?
|
| Radiation, Ionizing | 4 | 2021 | 123 | 0.250 |
Why?
|
| Enzyme Inhibitors | 6 | 2018 | 638 | 0.250 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2017 | 314 | 0.250 |
Why?
|
| Neoplasm Proteins | 2 | 2021 | 537 | 0.240 |
Why?
|
| Patient Selection | 3 | 2022 | 688 | 0.240 |
Why?
|
| Pituitary Neoplasms | 1 | 2006 | 73 | 0.230 |
Why?
|
| Bone Marrow | 1 | 2007 | 408 | 0.230 |
Why?
|
| Sphingomyelin Phosphodiesterase | 4 | 2000 | 20 | 0.230 |
Why?
|
| Clinical Competence | 3 | 2018 | 810 | 0.230 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 888 | 0.230 |
Why?
|
| Gene Expression Profiling | 4 | 2020 | 1517 | 0.230 |
Why?
|
| Amphiregulin | 1 | 2025 | 14 | 0.220 |
Why?
|
| Bevacizumab | 5 | 2021 | 254 | 0.220 |
Why?
|
| Animals | 22 | 2025 | 27973 | 0.220 |
Why?
|
| Naphthalenes | 4 | 1999 | 40 | 0.220 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2021 | 636 | 0.220 |
Why?
|
| Mice | 15 | 2025 | 12230 | 0.220 |
Why?
|
| Dacarbazine | 2 | 2015 | 100 | 0.210 |
Why?
|
| Follow-Up Studies | 7 | 2021 | 3814 | 0.210 |
Why?
|
| Melanoma | 2 | 2023 | 494 | 0.210 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2024 | 29 | 0.210 |
Why?
|
| Program Development | 2 | 2015 | 129 | 0.210 |
Why?
|
| Melanoma, Experimental | 1 | 2024 | 112 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2021 | 1447 | 0.210 |
Why?
|
| Radiotherapy, Image-Guided | 2 | 2016 | 66 | 0.200 |
Why?
|
| Radioimmunotherapy | 1 | 2023 | 29 | 0.200 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2024 | 66 | 0.200 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2024 | 161 | 0.190 |
Why?
|
| Adenocarcinoma | 5 | 2012 | 1171 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2020 | 2562 | 0.190 |
Why?
|
| Neoplasm Staging | 7 | 2024 | 2009 | 0.190 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2024 | 129 | 0.190 |
Why?
|
| Radiometry | 3 | 2014 | 60 | 0.180 |
Why?
|
| Radiation Pneumonitis | 1 | 2022 | 23 | 0.180 |
Why?
|
| Neoplasms, Second Primary | 3 | 2015 | 244 | 0.180 |
Why?
|
| Skin | 2 | 2016 | 575 | 0.180 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2014 | 278 | 0.180 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2018 | 193 | 0.180 |
Why?
|
| Anetoderma | 1 | 2021 | 2 | 0.170 |
Why?
|
| Re-Irradiation | 1 | 2021 | 17 | 0.170 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2021 | 8 | 0.170 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 49 | 0.170 |
Why?
|
| Mastectomy, Segmental | 3 | 2011 | 108 | 0.170 |
Why?
|
| Membrane Proteins | 2 | 2024 | 1260 | 0.170 |
Why?
|
| Exanthema | 1 | 2021 | 39 | 0.170 |
Why?
|
| Erythroid Precursor Cells | 1 | 2021 | 33 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 106 | 0.170 |
Why?
|
| Benzophenanthridines | 5 | 2000 | 22 | 0.170 |
Why?
|
| Alkaloids | 5 | 2000 | 47 | 0.160 |
Why?
|
| Butyrates | 1 | 2021 | 56 | 0.160 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 555 | 0.160 |
Why?
|
| Cell Line, Tumor | 8 | 2025 | 2757 | 0.160 |
Why?
|
| NF-kappa B | 1 | 2023 | 408 | 0.160 |
Why?
|
| Dendritic Cells | 1 | 2024 | 538 | 0.160 |
Why?
|
| Gliosarcoma | 1 | 2020 | 10 | 0.160 |
Why?
|
| Cytochrome c Group | 1 | 2000 | 82 | 0.160 |
Why?
|
| Memantine | 1 | 2020 | 10 | 0.160 |
Why?
|
| Critical Pathways | 1 | 2020 | 36 | 0.160 |
Why?
|
| Patient Care Management | 1 | 2020 | 29 | 0.160 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2020 | 92 | 0.160 |
Why?
|
| Motivation | 1 | 2022 | 310 | 0.150 |
Why?
|
| Risk Factors | 4 | 2018 | 5900 | 0.150 |
Why?
|
| Time Factors | 6 | 2020 | 5380 | 0.150 |
Why?
|
| Sphingomyelins | 2 | 1996 | 15 | 0.150 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2016 | 71 | 0.150 |
Why?
|
| Internship and Residency | 3 | 2018 | 1074 | 0.150 |
Why?
|
| Down-Regulation | 2 | 2017 | 523 | 0.150 |
Why?
|
| Body Mass Index | 2 | 2014 | 806 | 0.150 |
Why?
|
| Tumor Burden | 4 | 2017 | 321 | 0.150 |
Why?
|
| Motion | 2 | 2017 | 95 | 0.150 |
Why?
|
| Retrospective Studies | 8 | 2023 | 10128 | 0.150 |
Why?
|
| Cells, Cultured | 4 | 2017 | 2827 | 0.150 |
Why?
|
| Glioma | 1 | 2021 | 298 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 874 | 0.150 |
Why?
|
| Sphingosine | 2 | 1997 | 72 | 0.140 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2018 | 188 | 0.140 |
Why?
|
| Myeloid Cells | 3 | 2025 | 119 | 0.140 |
Why?
|
| Organs at Risk | 4 | 2021 | 55 | 0.140 |
Why?
|
| Regression Analysis | 2 | 2011 | 573 | 0.140 |
Why?
|
| Cone-Beam Computed Tomography | 2 | 2020 | 78 | 0.140 |
Why?
|
| Palliative Medicine | 1 | 2018 | 11 | 0.140 |
Why?
|
| Mediastinum | 1 | 2018 | 42 | 0.140 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2019 | 147 | 0.140 |
Why?
|
| Breath Holding | 1 | 2018 | 25 | 0.140 |
Why?
|
| Educational Measurement | 2 | 2018 | 236 | 0.140 |
Why?
|
| Astrocytoma | 1 | 2018 | 85 | 0.140 |
Why?
|
| Feasibility Studies | 3 | 2021 | 753 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 94 | 0.140 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 157 | 0.140 |
Why?
|
| United States | 11 | 2018 | 7581 | 0.140 |
Why?
|
| Neoplasms, Experimental | 1 | 2019 | 259 | 0.130 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 60 | 0.130 |
Why?
|
| Radiation Oncologists | 1 | 2017 | 15 | 0.130 |
Why?
|
| Societies, Scientific | 1 | 2017 | 41 | 0.130 |
Why?
|
| Education, Medical, Graduate | 2 | 2018 | 425 | 0.130 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2018 | 162 | 0.130 |
Why?
|
| Craniocerebral Trauma | 1 | 1997 | 52 | 0.130 |
Why?
|
| Transcription Factors | 2 | 2023 | 1687 | 0.130 |
Why?
|
| Credentialing | 1 | 2016 | 15 | 0.120 |
Why?
|
| Isoenzymes | 1 | 1997 | 271 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2014 | 512 | 0.120 |
Why?
|
| Hippocampus | 1 | 2020 | 451 | 0.120 |
Why?
|
| Lymph Nodes | 2 | 2014 | 550 | 0.120 |
Why?
|
| Selection Bias | 1 | 2016 | 37 | 0.120 |
Why?
|
| Terminology as Topic | 1 | 2017 | 219 | 0.120 |
Why?
|
| Benchmarking | 1 | 2016 | 80 | 0.120 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 381 | 0.120 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2016 | 83 | 0.120 |
Why?
|
| Biopsy | 2 | 2018 | 1172 | 0.120 |
Why?
|
| Mammography | 2 | 2010 | 494 | 0.120 |
Why?
|
| Standard of Care | 1 | 2016 | 69 | 0.110 |
Why?
|
| Teaching | 1 | 2016 | 138 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 5 | 2000 | 1022 | 0.110 |
Why?
|
| Cognition | 1 | 2020 | 625 | 0.110 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2015 | 87 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 338 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 333 | 0.110 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2015 | 134 | 0.110 |
Why?
|
| Lymphocytes | 1 | 1997 | 453 | 0.110 |
Why?
|
| Radiotherapy Setup Errors | 1 | 2014 | 2 | 0.110 |
Why?
|
| Disease Management | 1 | 2017 | 357 | 0.110 |
Why?
|
| Benzimidazoles | 1 | 2015 | 112 | 0.110 |
Why?
|
| Robotics | 1 | 2017 | 267 | 0.110 |
Why?
|
| Guidelines as Topic | 1 | 2015 | 163 | 0.110 |
Why?
|
| Needs Assessment | 2 | 2014 | 167 | 0.110 |
Why?
|
| Medical Oncology | 1 | 2018 | 403 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 873 | 0.100 |
Why?
|
| Boston | 1 | 2014 | 36 | 0.100 |
Why?
|
| Patient Positioning | 1 | 2014 | 65 | 0.100 |
Why?
|
| Hodgkin Disease | 1 | 2015 | 144 | 0.100 |
Why?
|
| Gene Transfer Techniques | 3 | 2001 | 154 | 0.100 |
Why?
|
| ErbB Receptors | 3 | 2025 | 504 | 0.100 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 595 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 290 | 0.100 |
Why?
|
| Consumer Behavior | 1 | 2014 | 31 | 0.100 |
Why?
|
| Pediatrics | 1 | 2018 | 378 | 0.100 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 308 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 557 | 0.100 |
Why?
|
| Metal Nanoparticles | 2 | 2010 | 35 | 0.100 |
Why?
|
| Gold | 2 | 2010 | 44 | 0.100 |
Why?
|
| Hospitals, Teaching | 1 | 2014 | 114 | 0.100 |
Why?
|
| Central Nervous System | 1 | 2014 | 139 | 0.100 |
Why?
|
| Carcinoma | 1 | 2016 | 439 | 0.100 |
Why?
|
| Young Adult | 8 | 2018 | 6922 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2014 | 305 | 0.090 |
Why?
|
| Child | 4 | 2018 | 7273 | 0.090 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2013 | 215 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2023 | 3044 | 0.090 |
Why?
|
| Enzyme Activation | 3 | 2000 | 672 | 0.090 |
Why?
|
| Analysis of Variance | 2 | 2012 | 883 | 0.090 |
Why?
|
| Eye Neoplasms | 1 | 2012 | 25 | 0.090 |
Why?
|
| Radiography, Thoracic | 1 | 2014 | 323 | 0.090 |
Why?
|
| Child, Preschool | 2 | 2016 | 3781 | 0.090 |
Why?
|
| Lung | 3 | 2014 | 1359 | 0.090 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2012 | 145 | 0.090 |
Why?
|
| Carcinoma, Large Cell | 1 | 2012 | 37 | 0.090 |
Why?
|
| Clinical Trials as Topic | 3 | 2017 | 1098 | 0.090 |
Why?
|
| Relative Biological Effectiveness | 2 | 2008 | 14 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2020 | 2434 | 0.090 |
Why?
|
| Reproducibility of Results | 5 | 2018 | 2705 | 0.080 |
Why?
|
| Neurosurgical Procedures | 1 | 2014 | 350 | 0.080 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2012 | 76 | 0.080 |
Why?
|
| Organ Size | 1 | 2011 | 360 | 0.080 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 347 | 0.080 |
Why?
|
| Deoxyglucose | 1 | 2010 | 38 | 0.080 |
Why?
|
| Pyrans | 1 | 2010 | 10 | 0.080 |
Why?
|
| Mortality | 1 | 2011 | 156 | 0.080 |
Why?
|
| Mice, Nude | 3 | 2010 | 823 | 0.080 |
Why?
|
| Acetamides | 1 | 2010 | 26 | 0.080 |
Why?
|
| Signal Transduction | 2 | 2023 | 3497 | 0.080 |
Why?
|
| Surveys and Questionnaires | 4 | 2018 | 2787 | 0.080 |
Why?
|
| Prodrugs | 2 | 2001 | 51 | 0.080 |
Why?
|
| Genes, p53 | 2 | 2001 | 108 | 0.080 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2009 | 41 | 0.080 |
Why?
|
| X-Ray Microtomography | 1 | 2010 | 102 | 0.080 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2024 | 148 | 0.080 |
Why?
|
| Adaptive Immunity | 2 | 2021 | 179 | 0.080 |
Why?
|
| Infant | 1 | 2016 | 3156 | 0.080 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2010 | 151 | 0.070 |
Why?
|
| Tamoxifen | 1 | 2010 | 170 | 0.070 |
Why?
|
| Chicago | 1 | 2014 | 1452 | 0.070 |
Why?
|
| Genetic Vectors | 2 | 2001 | 422 | 0.070 |
Why?
|
| Contrast Media | 2 | 2010 | 986 | 0.070 |
Why?
|
| Ethanolamines | 2 | 2000 | 24 | 0.070 |
Why?
|
| Oleic Acids | 2 | 2000 | 26 | 0.070 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2008 | 25 | 0.070 |
Why?
|
| Endocannabinoids | 2 | 2000 | 27 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 1999 | 111 | 0.070 |
Why?
|
| Cisplatin | 2 | 2007 | 567 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2013 | 1732 | 0.070 |
Why?
|
| Radiation Dosage | 2 | 2023 | 224 | 0.070 |
Why?
|
| Respiratory Mechanics | 1 | 2008 | 108 | 0.070 |
Why?
|
| Leukopenia | 1 | 2007 | 64 | 0.070 |
Why?
|
| Transplantation, Heterologous | 2 | 2000 | 371 | 0.070 |
Why?
|
| Mice, Knockout | 2 | 2024 | 2121 | 0.060 |
Why?
|
| Pelvis | 1 | 2007 | 99 | 0.060 |
Why?
|
| Recurrence | 1 | 2010 | 1188 | 0.060 |
Why?
|
| Actins | 1 | 2010 | 467 | 0.060 |
Why?
|
| Cell Division | 2 | 2000 | 689 | 0.060 |
Why?
|
| Neutropenia | 1 | 2007 | 209 | 0.060 |
Why?
|
| Drug Synergism | 2 | 1999 | 313 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2010 | 584 | 0.060 |
Why?
|
| Carboplatin | 2 | 2024 | 321 | 0.060 |
Why?
|
| Thrombocytopenia | 1 | 2007 | 189 | 0.060 |
Why?
|
| Anemia | 1 | 2007 | 129 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2024 | 2479 | 0.060 |
Why?
|
| Stereotaxic Techniques | 1 | 2006 | 81 | 0.060 |
Why?
|
| Phantoms, Imaging | 1 | 2009 | 479 | 0.060 |
Why?
|
| Disease Progression | 3 | 2018 | 1529 | 0.060 |
Why?
|
| Age Factors | 1 | 2010 | 1898 | 0.060 |
Why?
|
| Lymphatic Metastasis | 3 | 2016 | 505 | 0.060 |
Why?
|
| Algorithms | 4 | 2018 | 1948 | 0.060 |
Why?
|
| Biomarkers | 3 | 2022 | 1905 | 0.060 |
Why?
|
| Phagocytosis | 1 | 2025 | 111 | 0.050 |
Why?
|
| Interferon-gamma | 2 | 2019 | 459 | 0.050 |
Why?
|
| Postoperative Care | 2 | 2017 | 232 | 0.050 |
Why?
|
| Chemokine CXCL10 | 1 | 2024 | 23 | 0.050 |
Why?
|
| Thoracic Wall | 2 | 2014 | 26 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 1703 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 181 | 0.050 |
Why?
|
| Etoposide | 1 | 2024 | 205 | 0.050 |
Why?
|
| Histones | 1 | 2006 | 361 | 0.050 |
Why?
|
| Ligands | 1 | 2025 | 476 | 0.050 |
Why?
|
| Software | 2 | 2017 | 669 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2004 | 234 | 0.050 |
Why?
|
| Bile Duct Neoplasms | 1 | 2004 | 91 | 0.050 |
Why?
|
| Heart | 2 | 2018 | 522 | 0.050 |
Why?
|
| Lymph Node Excision | 1 | 2005 | 233 | 0.050 |
Why?
|
| Stomach Neoplasms | 1 | 2006 | 305 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 3431 | 0.050 |
Why?
|
| Palliative Care | 1 | 2004 | 268 | 0.050 |
Why?
|
| Immune Tolerance | 1 | 2025 | 378 | 0.050 |
Why?
|
| Quality of Life | 2 | 2021 | 1776 | 0.050 |
Why?
|
| Technology, Radiologic | 2 | 2016 | 103 | 0.040 |
Why?
|
| Models, Biological | 1 | 2008 | 1768 | 0.040 |
Why?
|
| Fatigue | 1 | 2021 | 181 | 0.040 |
Why?
|
| Vancomycin | 1 | 2021 | 75 | 0.040 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2010 | 137 | 0.040 |
Why?
|
| Prone Position | 1 | 2020 | 61 | 0.040 |
Why?
|
| Risk Management | 1 | 2020 | 38 | 0.040 |
Why?
|
| Antiparkinson Agents | 1 | 2020 | 16 | 0.040 |
Why?
|
| Permeability | 1 | 2000 | 143 | 0.040 |
Why?
|
| Placebos | 1 | 2020 | 205 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2021 | 655 | 0.040 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 133 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2011 | 526 | 0.040 |
Why?
|
| Cytokines | 1 | 2023 | 862 | 0.040 |
Why?
|
| Photochemotherapy | 1 | 1999 | 100 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 130 | 0.040 |
Why?
|
| Self-Assessment | 1 | 2018 | 44 | 0.040 |
Why?
|
| Radiation Tolerance | 1 | 2019 | 175 | 0.040 |
Why?
|
| Body Weight | 1 | 2000 | 449 | 0.040 |
Why?
|
| Training Support | 1 | 2018 | 22 | 0.030 |
Why?
|
| Interdisciplinary Studies | 1 | 2018 | 19 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2020 | 550 | 0.030 |
Why?
|
| Spirometry | 1 | 2018 | 77 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 2004 | 714 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2015 | 1518 | 0.030 |
Why?
|
| Cognition Disorders | 1 | 2020 | 235 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2018 | 354 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2021 | 501 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 1909 | 0.030 |
Why?
|
| Virus Replication | 1 | 1999 | 284 | 0.030 |
Why?
|
| Ceramidases | 1 | 1997 | 4 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2017 | 90 | 0.030 |
Why?
|
| Reference Standards | 1 | 2017 | 145 | 0.030 |
Why?
|
| Amidohydrolases | 1 | 1997 | 17 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2021 | 463 | 0.030 |
Why?
|
| Endopeptidases | 1 | 1997 | 114 | 0.030 |
Why?
|
| Gene Expression Regulation | 2 | 2023 | 1980 | 0.030 |
Why?
|
| Head | 1 | 2017 | 131 | 0.030 |
Why?
|
| Linear Models | 2 | 2009 | 413 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 283 | 0.030 |
Why?
|
| Bacteria | 1 | 2021 | 508 | 0.030 |
Why?
|
| Respiration | 1 | 2018 | 268 | 0.030 |
Why?
|
| Proton Therapy | 1 | 2016 | 39 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 77 | 0.030 |
Why?
|
| Hydrolysis | 1 | 1996 | 140 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2016 | 154 | 0.030 |
Why?
|
| Mitochondria | 1 | 2000 | 612 | 0.030 |
Why?
|
| Research Personnel | 1 | 2016 | 78 | 0.030 |
Why?
|
| Artifacts | 1 | 2017 | 241 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2020 | 1727 | 0.030 |
Why?
|
| Stomach | 1 | 2016 | 110 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 1581 | 0.030 |
Why?
|
| Deception | 1 | 2015 | 19 | 0.030 |
Why?
|
| Cell Movement | 1 | 2019 | 804 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2014 | 606 | 0.030 |
Why?
|
| Competitive Behavior | 1 | 2015 | 29 | 0.030 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1999 | 376 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1998 | 453 | 0.030 |
Why?
|
| School Admission Criteria | 1 | 2015 | 29 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 401 | 0.030 |
Why?
|
| Spinal Cord | 1 | 2016 | 236 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2015 | 60 | 0.030 |
Why?
|
| Lymphatic Irradiation | 1 | 2014 | 7 | 0.030 |
Why?
|
| Lymphoma, B-Cell | 1 | 1996 | 107 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 1997 | 601 | 0.030 |
Why?
|
| Genes, APC | 1 | 1994 | 25 | 0.030 |
Why?
|
| Rotation | 1 | 2014 | 90 | 0.030 |
Why?
|
| Liposomes | 1 | 1994 | 95 | 0.030 |
Why?
|
| Surgical Instruments | 1 | 2014 | 61 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 1999 | 1114 | 0.030 |
Why?
|
| Paclitaxel | 2 | 2006 | 478 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 753 | 0.020 |
Why?
|
| Necrosis | 1 | 2014 | 203 | 0.020 |
Why?
|
| Self Concept | 1 | 2014 | 135 | 0.020 |
Why?
|
| Equipment Design | 1 | 2014 | 411 | 0.020 |
Why?
|
| Data Collection | 1 | 2014 | 370 | 0.020 |
Why?
|
| Adolescent | 2 | 2015 | 9550 | 0.020 |
Why?
|
| Internet | 1 | 2014 | 345 | 0.020 |
Why?
|
| Decision Making | 1 | 2016 | 671 | 0.020 |
Why?
|
| Colon | 1 | 1994 | 540 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2011 | 258 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2011 | 391 | 0.020 |
Why?
|
| SEER Program | 1 | 2011 | 235 | 0.020 |
Why?
|
| Gene Expression | 1 | 1994 | 1304 | 0.020 |
Why?
|
| Neural Stem Cells | 1 | 2011 | 68 | 0.020 |
Why?
|
| Spiro Compounds | 1 | 2010 | 22 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2011 | 283 | 0.020 |
Why?
|
| Drug Design | 1 | 2010 | 133 | 0.020 |
Why?
|
| Biological Transport | 1 | 2010 | 398 | 0.020 |
Why?
|
| Cervical Vertebrae | 1 | 2012 | 228 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2013 | 660 | 0.020 |
Why?
|
| Body Burden | 1 | 2008 | 10 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 1054 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 1339 | 0.010 |
Why?
|
| Leucovorin | 1 | 2006 | 200 | 0.010 |
Why?
|
| Mandibular Diseases | 1 | 2005 | 17 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2006 | 279 | 0.010 |
Why?
|
| Osteoradionecrosis | 1 | 2005 | 18 | 0.010 |
Why?
|
| Hydroxyurea | 1 | 2005 | 231 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2006 | 266 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2009 | 578 | 0.010 |
Why?
|
| Mastectomy, Radical | 1 | 2005 | 10 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2012 | 1269 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2005 | 291 | 0.010 |
Why?
|
| Camptothecin | 1 | 2005 | 195 | 0.010 |
Why?
|
| Deoxycytidine | 1 | 2005 | 207 | 0.010 |
Why?
|
| Neuroectodermal Tumors | 1 | 2004 | 2 | 0.010 |
Why?
|
| Axilla | 1 | 2005 | 109 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2008 | 1120 | 0.010 |
Why?
|
| DNA Damage | 1 | 2006 | 389 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2006 | 404 | 0.010 |
Why?
|
| Survival | 1 | 2003 | 21 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2004 | 244 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 984 | 0.010 |
Why?
|
| Rats | 2 | 1998 | 4028 | 0.010 |
Why?
|
| Biotransformation | 1 | 1998 | 46 | 0.010 |
Why?
|
| Cell Death | 1 | 1999 | 252 | 0.010 |
Why?
|
| Light | 1 | 1998 | 286 | 0.010 |
Why?
|
| Adenoviridae | 1 | 1997 | 340 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1999 | 1908 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 1994 | 65 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1994 | 1236 | 0.010 |
Why?
|
| Base Sequence | 1 | 1994 | 2207 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1994 | 2889 | 0.000 |
Why?
|
| Intestinal Mucosa | 1 | 1994 | 825 | 0.000 |
Why?
|